Losartan and other angiotensin receptor blockers (DrugBank: Losartan, Angiotensin)
18 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
17 | 多系統萎縮症 | 0 |
19 | ライソゾーム病 | 1 |
36 | 表皮水疱症 | 0 |
46 | 悪性関節リウマチ | 0 |
58 | 肥大型心筋症 | 0 |
66 | IgA腎症 | 0 |
67 | 多発性嚢胞腎 | 0 |
85 | 特発性間質性肺炎 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
98 | 好酸球性消化管疾患 | 0 |
113 | 筋ジストロフィー | 0 |
164 | 眼皮膚白皮症 | 0 |
167 | マルファン症候群 | 0 |
179 | ウィリアムズ症候群 | 0 |
215 | ファロー四徴症 | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00446862 (ClinicalTrials.gov) | March 2007 | 11/3/2007 | The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study | Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study | Fabry Disease;Proteinuria | Drug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers | University of Alabama at Birmingham | NULL | Completed | 19 Years | 85 Years | Both | 36 | N/A | United States;Slovenia;Germany |